Endocrinologic and Metabolic Drugs Advisory Committee
Committee March 28, 2012 from 8:00 to 5:00 (Day 1 of 2)
Agenda: On both days, the committee will discuss the role of cardiovascular assessment in the preapproval and postapproval settings for drugs and biologics developed for the treatment of obesity.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment